1. Market Research
  2. > Sylentis – Product Pipeline Review – 2013

Sylentis – Product Pipeline Review – 2013

  • May 2013
  • -
  • Global Markets Direct
  • -
  • 29 pages

Sylentis – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Sylentis - Product Pipeline Review - 2013” provides data on the Sylentis’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Sylentis’s corporate website, SEC filings, investor presentations and featured press releases, both from Sylentis and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Sylentis - Brief Sylentis overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Sylentis human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Sylentis with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Sylentis’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Sylentis’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Sylentis in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Sylentis’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Sylentis.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Sylentis and identify potential opportunities in those areas.

Table Of Contents

Sylentis - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Sylentis Snapshot 5
Sylentis Overview 5
Key Information 5
Key Facts 5
Sylentis - Research and Development Overview 6
Key Therapeutic Areas 6
Sylentis - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Sylentis - Pipeline Products Glance 10
Sylentis Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Sylentis - Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Sylentis - Drug Profiles 13
Drug For Arthritis 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Drug For Cerebral Ischemia 14
Product Description 14
Mechanism of Action 14
RandD Progress 14
Drug For Crohn's Disease And Ulcerative Colitis 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
Drug For Dementia 16
Product Description 16
Mechanism of Action 16
RandD Progress 16
SYL-040012 17
Product Description 17
Mechanism of Action 17
RandD Progress 17
SYL-1001 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
Sylentis - Pipeline Products by Route of Administration 20
Sylentis - Pipeline Products By Mechanism of Action 21
Sylentis - Recent Pipeline Updates 22
Sylentis - Locations And Subsidiaries 23
Head Office 23
Sylentis, Recent Developments 24
Sylentis- Press Release 24
Feb 27, 2013: Sylentis Commences Phase II Clinical Trials With SY1001 For Treating Eye Discomfort Associated With Dry Eye Syndrome 24
Sep 06, 2010: Sylentis Receives Authorization To Commence Phase I/II Clinical Trial With SYL040012 For Treating Elevated Intraocular Pressure And Glaucoma 24
Jul 06, 2010: Sylentis Completes Phase I trial With SYL040012 To Treat Elevated Intraocular Pressure And Glaucoma 25
Financial Deals Landscape 26
Sylentis, Deals Summary 26
Sylentis, Pharmaceuticals and Healthcare, Deal Details 27
Licensing Agreements 27
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 29
Disclaimer 29



List of Tables

Sylentis, Key Information 5
Sylentis, Key Facts 5
Sylentis - Pipeline by Indication, 2013 7
Sylentis - Pipeline by Stage of Development, 2013 8
Sylentis - Monotherapy Products in Pipeline, 2013 9
Sylentis - Phase II, 2013 10
Sylentis - Pre-Clinical, 2013 11
Sylentis - Discovery, 2013 12
Sylentis - Pipeline By Route of Administration, 2013 20
Sylentis - Pipeline Products By Mechanism of Action, 2013 21
Sylentis - Recent Pipeline Updates, 2013 22
Sylentis, Deals Summary 26
Alnylam Pharma Enters Into Option Licensing Agreement With Sylentis 27



List of Figures

Sylentis - Pipeline by Indication, 2013 7
Sylentis - Pipeline by Stage of Development, 2013 8
Sylentis - Monotherapy Products in Pipeline, 2013 9
Sylentis - Pipeline By Route of Administration, 2013 20
Sylentis - Pipeline Products By Mechanism of Action, 2013 21

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.